hsa-mir-661: Hsa-mir-661 is a microRNA that has been identified as a candidate for promoting breast cancer development [PMC5308650]. However, it has also been found to be involved in blood mononuclear cells and the cortex of Alzheimer's patients [PMC7748118]. In Alzheimer's patients, the expression level of hsa-mir-661 is downregulated compared to healthy controls [PMC7748118]. Hsa-mir-661 has also been identified as a potential target for circRNAs in melanoma and colorectal cancer [PMC9740358] [PMC4516543]. Interestingly, hsa-mir-661, along with hsa-miR-494-3p, has been studied to predict potential target genes and signaling pathways in order to gain a better understanding of their roles in disease progression [PMC7748118]. Ontology analysis of hsa-mir-661 has revealed enrichment in various cellular processes such as the mitotic cell cycle, apoptotic signaling pathway, viral process, and cell death pathway [PMC8778063]. These findings suggest that hsa-mir-661 may play important roles in cancer development and progression.

MIR661: MIR661, a type of microRNA, has been investigated for its impact on cellular metabolism [PMC5709620]. A study found that the basal extracellular acidification rate (ECAR) of MIR661 cells was significantly affected compared to control cells, indicating disruption in glucose and glycolytic intermediates within the cells [PMC5709620]. Metabolomic analysis conducted in the study supported this observation [PMC5709620]. The researchers specifically focused on the DLD1 non-metastatic cell line, which exhibited lower levels of MIR661 expression compared to primary colon cell lines (Ccd18-Co and CCD841) [PMC5709620]. This selection aimed to explore the potential role of MIR661 in non-metastatic cells and its impact on cellular metabolism [PMC5709620].